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ABSTRACT
Introduction In proliferative diabetic retinopathy (PDR),
vascular endothelial growth factor (VEGF) and connective
tissue growth factor (CTGF) may cause blindness by
neovascularisation followed by ﬁbrosis of the retina. It
has previously been shown that a shift in the balance
between levels of CTGF and VEGF in the eye is
associated with this angioﬁbrotic switch. This study
investigated whether anti-VEGF agents induce
accelerated ﬁbrosis in patients with PDR, as predicted by
this model.
Methods CTGF and VEGF levels were measured by
ELISA in 52 vitreous samples of PDR patients, of which
24 patients had received intravitreal bevacizumab
1 week to 3 months before vitrectomy, and were
correlated with the degree of vitreoretinal ﬁbrosis as
determined clinically and intra-operatively.
Results CTGF correlated positively, and VEGF correlated
negatively with the degree of ﬁbrosis. The CTGF/VEGF
ratio was the strongest predictor of ﬁbrosis. Clinically,
increased ﬁbrosis was observed after intravitreal
bevacizumab.
Conclusions These results conﬁrm that the CTGF/VEGF
ratio is a strong predictor of vitreoretinal ﬁbrosis in PDR,
and show that intravitreal anti-VEGF treatment causes
increased ﬁbrosis in PDR patients. These ﬁndings provide
strong support for the model that the balance of CTGF
and VEGF determines the angioﬁbrotic switch, and
identify CTGF as a possible therapeutic target in the
clinical management of PDR.
Proliferative diabetic retinopathy (PDR) is a major
cause of blindness. PDR is characterised by neovas-
cularisation due to retinal ischaemia, and subse-
quent vitreoretinal ﬁbrosis.
1 PDR is a wound
healing-like response, in which newly formed vessels
may progress to form ﬁbrovascular tissue, which can
cause traction on the retina, resulting in retinal
detachment and blindness. At some point during
this process there is a transition from angiogenesis
to ﬁbrosis, which we have introduced as the angio-
ﬁbrotic switch.
2 The mechanisms underlying this
switch have not been fully elucidated.
Several growth factors play a role in the different
phases of PDR. The pro-angiogenic cytokine
vascular endothelial growth factor (VEGF) is
considered to be the primary factor involved in
neovascularisation in PDR.
3 A possible causal factor
of ﬁbrosis in PDR is connective tissue growth factor
(CTGF). CTGF, a member of the CCN family of
matricellular proteins, is also known as CCN2. It is
a cytokine with proﬁbrotic activity in various other
organs and diseases, and is associated with ﬁbrosis
in vitreoretinal disorders, including diabetic reti-
nopathy.
24VEGF and CTGF have been shown to
interact. VEGF can induce CTGF expression,
5e7 and
CTGF can inhibit VEGF-induced angiogenesis by
CTGFeVEGF protein binding.
89
We recently investigated the correlation of
vitreous CTGF levels with angiogenesis, ﬁbrosis
and VEGF levels in PDR, and demonstrated that
the ratio between CTGF and VEGF levels is
a strong predictor of the angioﬁbrotic switch in
PDR.
2 This would imply that increasing CTGF
levels and/or decreasing VEGF levels shift the
balance between CTGF and VEGF causing the
angioﬁbrotic switch that drives ﬁbrosis.
Intravitreal administration of anti-VEGF anti-
bodies, most commonly bevacizumab and ranibi-
zumab, has become increasingly important in the
treatment of PDR. Bevacizumab (Avastin; Genen-
tech, San Francisco, California, USA) is a full-length
recombinant humanised anti-VEGF monoclonal
antibody, approved by the US Food and Drug
Administration for the treatment of colorectal
cancer.
10 In the eye, bevacizumab is used off-label
for neovascular age-related macular degeneration
11
and for diabetic macular oedema.
12 13 Furthermore,
intravitreal injections of bevacizumab have been
used as an adjunct to vitreoretinal surgery in PDR.
It facilitates surgery by reducing iris and retinal
neovascularisation,
14 thereby limiting intra-
operative bleeding from new vessels.
15 Bevaci-
zumab also reduces early postoperative vitreous
cavity haemorrhage.
16 17 In cases of tractional
retinal detachment (TRD), bevacizumab minimises
bleeding during the peeling of ﬁbrovascular
membranes.
18
However, bevacizumab may increase the risk of
ﬁbrotic complications. Progression or development
of TRD shortly after bevacizumab has been
reported.
19 Also, a ﬁbrotic switch has been observed
in diabetic ﬁbrovascular proliferative membranes
after bevacizumab.
20
Our model suggests a critical balance between
VEGF and CTGF as a determinant of the disease
course in PDR, in particular the angioﬁbrotic
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Laboratory scienceswitch. It predicts that a reduction in VEGF levels, by causing
a shift in the CTGF/VEGF balance in favour of CTGF, leads to
accelerated ﬁbrosis. In the present study, we aimed to conﬁrm
our previously observed correlation of the CTGF/VEGF ratio
with ﬁbrosis in an independent cohort of patients with PDR. In
addition, we investigated whether anti-VEGF treatment leads to
increased ﬁbrosis in PDR patients, as predicted by our model
that the balance of CTGF and VEGF in the vitreous determines
the clinical course of PDR.
MATERIALS AND METHODS
Patients
Vitreous samples were collected from 52 consecutive patients
with PDR undergoing vitrectomy. The main exclusion criteria
were signiﬁcant ocular co-morbidity, previous vitrectomy, and
ocular surgery within 3 months of vitrectomy. Twenty-eight
patients with PDR had not been treated with anti-VEGF at any
time (PDR group). Seventeen PDR patients had received a single
intravitreal injection of 1.25 mg bevacizumab as adjunct within
1 week before vitrectomy (bevacizumab 1 group). A group of
seven patients had received bevacizumab and were operated at
least 4 weeks later (bevacizumab 2 group). All but six patients
(three PDR and three bevacizumab 1) had previous panretinal
photocoagulation laser treatment. The study was conducted
according to the tenets of the Declaration of Helsinki and
informed consent was obtained from all patients. The Institu-
tional Review Board of the Academic Medical Center at the
University of Amsterdam approved the study.
Preoperative ophthalmic and ultrasound examinations,
patient ﬁles and peri-perative observations allowed grading of
ﬁbrosis, determination of the presence of haemorrhage and type
of diabetes with a standardised form. Fibrosis was graded
0 when there was no ﬁbrosis, 1 when preretinal membranes
were found as in epiretinal membrane/macular pucker, 2 when
white preretinal ﬁbrotic membranes were found with limited
extension into the vitreous, and 3 when abundant white
membranes were found reaching into the vitreous body.
Sample collection and ELISA
Undiluted vitreous samples (0.5e1 ml) were obtained by using
a vitrectome at the start of a three-port pars plana vitrectomy
with the infusion line in position but not opened. The vitreous
was transferred to sterile Eppendorf tubes and immediately
frozen in dry ice in duplicate. The samples were kept at  808C
until assayed.
After thawing, vitreous samples were centrifuged at 20000g
for 15 min at 48C, and supernatant was collected. Concentra-
tions of VEGF165 were determined by the Quantikine ELISA
assay according to the manufacturer’s protocol (R&D Systems,
Minneapolis, Minnesota, USA). Concentrations of CTGF were
determined by sandwich ELISA, using two distinct monoclonal
antibodies speciﬁcally recognising the N-terminal part of the
CTGF protein (FibroGen, San Francisco, California, USA), as
described previously.
21 Puriﬁed recombinant human CTGF
(FibroGen) was used as standard.
Statistical analysis
The growth factor levels in vitreous were tested for normal
distribution using histograms and the ShapiroeWilk test. VEGF
levels showed a left skewed distribution, and were log10 trans-
formed when appropriate. Differences in the degree of ﬁbrosis
were assessed using the c
2 test. Differences in growth factor
levels were assessed by the non-parametric ManneWhitney U
test. Correlations were expressed as Spearman’s correlation
coefﬁcient; a r value of 0.5 or higher was considered relevant.
Univariate and multiple ordinal logistic regression analyses were
performed with the degree of ﬁbrosis as dependent variable, and
outcomes were expressed as OR with a 95% CI. A two-tailed
p value less than 0.05 was considered to indicate statistical
differences. All analyses were carried out using PASW Statistics
(V.18) software (SPSS, Chicago, Illinois, USA).
RESULTS
CTGF levels correlated with the degree of ﬁbrosis (ﬁgure 1),
with a Spearman’s r value of 0.6 (p<0.001). VEGF levels corre-
lated negatively with ﬁbrosis (r  0.5; p¼0.001). The ratio of
CTGF/log10(VEGF) levels (CTGF/VEGF ratio) had an even
stronger correlation with the degree of ﬁbrosis (r 0.7; p<0.001;
ﬁgure 1). VEGF and CTGF levels did not correlate (p>0.05). Also,
CTGFand VEGF levels did not correlate with age, gender, diabetes
type or vitreous haemorrhage (all p>0.05). Patient characteristics
and vitreous CTGF and VEGF levels are presented in table 1.
Univariate ordinal regression analysis to determine the
strongest predictor of ﬁbrosis of the retina showed that both
CTGF levels and VEGF levels were signiﬁcantly associated with
the degree of ﬁbrosis: CTGF associated positively and VEGF
associated negatively with ﬁbrosis (table 2). Furthermore,
a signiﬁcant association with ﬁbrosis was found for the CTGF/
VEGF ratio. In a multivariate model with both CTGF and VEGF
levels as predictors of ﬁbrosis, similar associations with the
degree of ﬁbrosis were found (table 2).
Subanalysis of PDR patients and bevacizumab patients
showed that the latter had a signiﬁcantly higher degree of
ﬁbrosis (p<0.001, c
2 test) and higher CTGF levels (p¼0.021,
ManneWhitney U test) compared with the other PDR patients.
We further reviewed the ﬁles of the seven PDR patients who
received bevacizumab and were operated at least 4 weeks later
(the bevacizumab 2 group). The median time interval between
Figure 1 Vitreous connective tissue
growth factor (CTGF) levels (A) and
CTGF/log10 (vascular endothelial growth
factor; VEGF) ratio (B) per degree of
ﬁbrosis of the retina. Filled symbols:
proliferative diabetic retinopathy group.
Open symbols: bevacizumab group;
means of each group are also
presented. (A) Vitreous CTGF levels and
degree of ﬁbrosis correlated
signiﬁcantly (Spearman’s r 0.6,
p<0.001). (B) The CTGF/log10(VEGF)
ratio and degree of ﬁbrosis correlated
signiﬁcantly (Spearman’s r 0.7, p<0.001).
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Laboratory sciencebevacizumab injection and vitrectomy was 11 weeks (range
4e26 weeks). The degree of ﬁbrosis had remained stable after
bevacizumab in two patients, who were already planned for
surgery because of retinal traction before bevacizumab.
However, the degree of ﬁbrosis increased in ﬁve patients. In these
patients, the development or increase of ﬁbrosis after bevaci-
zumab was the indication to perform vitrectomy. Overall, the
degree of ﬁbrosis increased signiﬁcantly after bevacizumab
(p¼0.038, Wilcoxon signed rank test).
Follow-up
Patients had a mean follow-up of 20.4 months (613.0) after
vitrectomy. Two of 17 patients in the bevacizumab 1 group
developed proliferative vitreoretinopathy and had a TRD at
6 weeks or 4 months after vitrectomy and delamination,
respectively. Both patients had grade 3 ﬁbrosis at the time of
operation, and signiﬁcantly higher vitreous CTGF levels
compared with all other bevacizumab 1 patients (p¼0.027) and
the highest CTGF/VEGF ratios of 39.1 and 40, respectively
(compare with ﬁgure 1). Interestingly, another patient in the
PDR group with a CTGF level comparable to these two beva-
cizumab 1 patients and grade 3 ﬁbrosis but with a low CTGF/
VEGF ratio of 3.3 did not develop proliferative vitreoretinopathy
or retinal detachment.
DISCUSSION
In the present study, we have conﬁrmed our previous ﬁndings
2 in
an independent group of 52 patients with diabetes that CTGF
(CCN2) levels are strongly correlated with the degree of vitreo-
retinal ﬁbrosis in PDR. In addition, we conﬁrmed that the CTGF/
VEGF ratio is the strongest predictor of ﬁbrosis in PDR patients,
including those treated with intravitreal anti-VEGF antibodies.
Retrospectively, ﬁve out of seven patients who received
bevacizumab and were operated at least 4 weeks later (the
bevacizumab 2 group), showed an increased degree of ﬁbrosis
after bevacizumab, ie, developed retinal ﬁbrosis or progressed to
TRD and therefore needed vitreoretinal surgery. In the 17
patients in the bevacizumab 1 group who were operated within
1 week after injection, progression of ﬁbrosis was not observed,
which may be due to the short time interval between bevaci-
zumab injection and vitrectomy. This suggests that the chance
that ﬁbrosis develops or progresses increases with time, possibly
due to prolonged high CTGF/VEGF ratios, which only gradually
decline after anti-VEGF treatment.
The post-bevacizumab ﬁbrotic phenomenon has been
observed previously in PDR as well as in age-related macular
degeneration.
20 22e25 In a series of 211 patients with PDR,
Arevalo et al
19 found progression or development of TRD after
bevacizumab injection in 11 (5.2%) patients. In this prospective
study, bevacizumab was administered as an adjunct for vitrec-
tomy and TRD was noted after a mean of 13 days after beva-
cizumab. Patients who did not develop TRD had their
vitrectomies earlier. The authors could not discern whether TRD
happened by natural history or by rapid neovascular involution
with accelerated ﬁbrosis as a response to decreased VEGF levels.
Based on our present ﬁndings, it can be stated that decreased
VEGF levels combined with elevated CTGF levels may well have
accelerated the ﬁbrotic response in these patients.
Is it possible that high CTGF levels combined with low VEGF
levels after anti-VEGF treatment also increase the risk of ﬁbrotic
complications after vitrectomy? During surgery, ﬁbrovascular
membranes are peeled and the vitreous, and thereby the pool of
growth factors, is removed. However, in the time interval
between bevacizumab and vitrectomy VEGF but not CTGF is
inactivated, and thus CTGF may well induce ﬁbrotic responses
in the retina or the vitreoretinal surface. As an example, two
patients in the bevacizumab 1 group developed TRD after
vitrectomy. These cases had the two highest CTGF levels and
CTGF/VEGF ratios that we encountered. In comparison, a PDR
patient with comparable CTGF levels and degree of ﬁbrosis, but
Table 1 Patient characteristics and data
Patient characteristics (n[52) Subcategory
Anti-VEGF treatment None PDR group n¼28
<1 week before surgery Bevacizumab 1 group n¼17
>4 weeks before surgery Bevacizumab 2 group n¼7
Age (mean6SD) 53.2614.2 years
Gender Male n¼32
Female n¼20
Diabetes type Type I n¼19
Type II n¼33
Degree of ﬁbrosis No ﬁbrosis (0) n¼10
Only few preretinal membranes (1) n¼3
Some proliferative membranes (2) n¼27
Abundant proliferative membranes (3) n¼12
Haemorrhage No haemorrhage (0) n¼8
Haemorrhage (1) n¼44
CTGF (geometric mean, 95% CI) 12.4 ng/ml (10.8e14.2)
VEGF (geometric mean, 95% CI) 121.9 pg/ml (66.4e223.9)
Ratio CTGF/log10(VEGF) (geometric
mean, 95% CI)
6.7 (5.3e8.4)
CTGF, connective tissue growth factor; PDR, proliferative diabetic retinopathy; VEGF, vascular endothelial growth factor.
Table 2 Predictors of ﬁbrosis of the retina in 52 diabetes patients
Variable Contrast
Degree of ﬁbrosis
OR (95% CI) p Value
Univariate ordinal regression
CTGF Per unit increase 1.38 (1.19 to 1.61) <0.001
VEGF Per 10-fold increase 0.35 (0.19 to 0.67) 0.001
Ratio CTGF/log10(VEGF) Per unit increase 1.27 (1.12 to 1.43) <0.001
Multiple ordinal regression*
CTGF Per unit increase 1.37 (1.16 to 1.60) <0.001
VEGF Per 10-fold increase 0.37 (0.18 to 0.78) 0.009
*CTGF and VEGF in model.
CTGF, connective tissue growth factor; VEGF, vascular endothelial growth factor.
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VEGF ratio, did not develop ﬁbrotic complications post-
operatively. This suggests that a high CTGF level in combina-
tion with low levels of VEGF after bevacizumab, even for a short
period of time, is a risk factor for the development of (late)
postoperative ﬁbrotic complications.
Anti-VEGF therapy is directed at the angiogenic stimulus for
retinal neovascularisation and its introduction has made a signif-
icant advance in the management of PDR. However, retinal
ﬁbrosis can develop or progress as a consequence. Therefore, the
development of adjuvant therapy targeted against pathways
other than the angiogenic pathway may be required in combi-
nation with anti-VEGF therapy. Our present study and other
studies in various organs and conditions
4 26 have identiﬁed CTGF
and in particular the CTGF/VEGF ratio in vitreous as markers of
ﬁbroproliferative disease. Targeting of the ﬁbrotic pathway with
anti-CTGF therapy may be an attractive option in combination
with anti-VEGF treatment to prevent the angioﬁbrotic switch in
PDR patients and other diseases with ocular angiogenesis.
In conclusion, we conﬁrmed that CTGF levels and in partic-
ular the CTGF/VEGF ratio in vitreous are associated with
vitreoretinal ﬁbrosis in PDR. These ﬁndings support our working
model that the balance of VEGF and CTGF in the vitreous in
PDR drives the course of the disease, in particular the angioﬁ-
brotic switch. As predicted by this model, anti-VEGF therapy
shifts the CTGF/VEGF ratio causing the angioﬁbrotic switch,
which may lead to harmful accelerated ﬁbrosis in PDR.
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